Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $16.1M | $13.9M |
| Revenue growth | — | — | — | — | — | -14.2% |
| Operating income | -$12.9M | -$69.7M | -$123M | -$82.2M | -$89.5M | -$84.4M |
| Operating margin | — | — | — | — | -554.1% | -609.2% |
| Net income | -$12.8M | -$76.0M | -$121M | -$73.8M | -$77.3M | -$79.6M |
| Net margin | — | — | — | — | -478.9% | -574.5% |
| EPS (diluted) | -$12.45 | -$8.95 | -$3.65 | -$1.85 | -$1.32 | -$1.28 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$10.1M | -$35.3M | -$89.3M | -$70.7M | -$57.7M | -$63.5M |
| Capital expenditures | $1.48M | $540K | $6.40M | $6.73M | $237K | $9.00K |
| Free cash flow | -$11.6M | -$35.9M | -$95.7M | -$77.4M | -$57.9M | -$63.5M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.08M | $275M | $179M | $9.66M | $19.5M | $15.4M |
| Total assets | $10.2M | $280M | $211M | $174M | $157M | $91.5M |
| Total liabilities | $3.85M | $18.7M | $50.6M | $48.0M | $36.4M | $38.1M |
| Shareholders' equity | -$15.6M | $261M | $161M | $126M | $121M | $53.4M |
| Retained earnings | -$15.7M | -$91.7M | -$212M | -$286M | -$364M | -$443M |
| Shares (wtd avg diluted) | 1.29M | 8.49M | 33.0M | 39.9M | 58.4M | 62.1M |
Every figure is extracted from Pyxis Oncology, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.